Roche will report new data on important progress for people with advanced cancers at ASCO 2012
16 May 2012 | By Roche
Phase III data on Avastin in advanced colorectal and ovarian cancers...
List view / Grid view
16 May 2012 | By Roche
Phase III data on Avastin in advanced colorectal and ovarian cancers...
7 May 2012 | By Roche
Roche announced that following the results of the second interim analysis of the dalcetrapib dal-OUTCOMES Phase III trial...
3 May 2012 | By Roche
Roche announced that the SUMMACTA study met its primary endpoint...
18 April 2012 | By Roche
Roche released the following statement based on preliminary estimates...
6 April 2012 | By Roche
Roche released the following statement in response to a report issued by Institutional Shareholder Services...
30 March 2012 | By Roche
Roche have announced topline results of EMILIA...
29 March 2012 | By Roche
Roche increases offer price for gene sequencing firm Illumina to US$ 51.00 per share...
13 March 2012 | By Roche
The 2nd request seeks additional information regarding Roche’s microarray business...
2 March 2012 | By Roche
Roche announced preliminary results from the ADACTA study...
27 February 2012 | By Roche
Roche has extended its cash tender offer to acquire all outstanding shares of Illumina, Inc. at a price of $44.50 per share...
20 February 2012 | By Roche
First and only personalized skin cancer medicine allows people with BRAF V600 mutation-positive metastatic melanoma to live significantly longer...
8 February 2012 | By Roche
The U.S. FDA has accepted the company’s Biologics License Application for pertuzumab...
30 January 2012 | By
The first medicine for adults with advanced basal cell carcinoma...
27 January 2012 | By Roche
Roche has commenced a cash tender offer to acquire all outstanding shares of Illumina, Inc....
26 January 2012 | By Roche
Roche has responded to an announcement from Illumina, Inc...